Billion-Dollar Vaccine Patent Agreement Leads to Significant Profits for Key Executives

Moderna has reached a global settlement with Genvant Sciences and Arbutus Biopharma to resolve all patent disputes surrounding SM-102-based mRNA vaccines, including Spikevax. Under the agreement, Moderna will pay a lump sum of $950 million by early July and up to an additional $1.3 billion depending on the outcomes of related proceedings, for a total potential payment of $2.25 billion (approximately ₩3 trillion).

On March 17, 2026, Eric Benkert, President of Roivant Sciences Ltd. (NASDAQ: ROIV) and CEO of its subsidiary Immunovant, exercised 200,000 stock options and immediately sold the same number of shares at around $28 each, realizing a cash gain of about $5.65 million (roughly ₩8 billion). As a result, his direct common-stock holdings declined by 200,000 shares, though his option rights on that quantity remain intact.

Alongside the announcement of the up to $2.25 billion global patent settlement, Roivant approved a $1 billion (approximately ₩1.3 trillion) share repurchase program. The company’s stock reached an intraday record high of $26.35 in February and has climbed more than 130 percent over the past year.

Roivant operates as a platform-model pharmaceutical and biotech holding company with numerous subsidiaries. Its equity stakes in Genvant and Arbutus give it substantial economic interests in the lipid nanoparticle (LNP) patents essential to mRNA vaccines. With the impending commercial launches of key pipeline assets such as the autoimmune therapy brepocitinib, Roivant is continuing its growth strategy as a “bioventure holding company” in the global immunology and rare-disease markets.